Drug Combination Details
| General Information of the Combination (ID: C21617) | |||||
|---|---|---|---|---|---|
| Name | Vinblastine | + | Brentuximab vedotin + Doxorubicin + Dacarbazine | ||
| Click to Show/Hide the Each NP or Drug Information of This Combination | |||||
| Name | Vinblastine NP Info | Drug Info | |||
| Structure |
|
|
|||
| Name | Drug Info | ||||
| Structure |
|
|
|||
| Name | Drug Info | ||||
| Structure |
|
|
|||
| Disease |
Human immunodeficiency virus disease
[ICD-11: 1C62]
|
Phase 2 | [1] | ||
|
Hodgkin lymphoma
[ICD-11: 2B30]
|
Investigative | [2] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Experimental
Result(s) |
The results of the ECHELON-1 study showed a significantly longer modified progression-free survival (mPFS) following BV+AVD than with ABVD in primary HL. | |||||
